In the ever-evolving world of biotech innovation, Indaptus Therapeutics (NASDAQ: INDP) has once again taken center stage—this time with the dosing of the first patient in its expansion arm of a Phase 1b/2 clinical trial. The star of the show? Decoy20, a novel immunotherapy candidate that’s less “wolf in sheep’s clothing” and more “friendly bacteria in a lab coat,” designed to rally the body’s immune system against some of the most stubborn solid tumors.
Indaptus Therapeutics, headquartered in the bustling heart of New York City, is not your average cancer-fighting outfit. With a team that can be counted on two hands and a penchant for scientific audacity, the company has built its platform on a century-old observation: sometimes, a brush with bacteria can prompt tumors to shrink. Rather than waiting for chance infections, Indaptus has engineered non-pathogenic, gram-negative bacteria—attenuated and killed for safety—that act as immune system “decoys.” These clever constructs are designed to activate both the innate and adaptive arms of the immune response, effectively sounding the alarm for the body’s natural defenses to target cancer cells.
The expansion arm of the current trial is particularly ambitious, combining Decoy20 with - BeOne Medicines Ltd.’s (NASDAQ: ONC) PD-1 inhibitor, tislelizumab. PD-1 inhibitors have already made waves in oncology. i.e. Merck's (MRK) multi-billion dollar a year blockbuster drug Keytruda, but not all patients respond, and long-term benefits can be elusive. The hope is that Decoy20, by priming the immune system in a broad and robust fashion, will help more patients respond to checkpoint inhibitors like tislelizumab—potentially turning the tide for those with advanced solid tumors.
The trial’s structure is as methodical as it is optimistic: patients first receive Decoy20 alone for a week, followed by the combination therapy. The safety review committee, ever the vigilant chaperone, has already given the nod for unrestricted enrollment at the lower Decoy20 dose, thanks to a safety profile that’s been, in clinical terms, “as expected”—with only transient, manageable side effects such as mild infusion reactions and temporary dips in blood pressure.
While Indaptus is still in the clinical stage and not yet profitable (a familiar refrain in biotech’s high-stakes symphony), it has been doing its best to keep its financial sheet in respectable order. Recent fundraising efforts have bolstered its cash position, and the company is strategically focusing resources on the most promising combination studies. Analyst sentiment remains buoyant, with price targets well above current trading levels—a testament to the scientific intrigue surrounding Decoy20.
What sets Indaptus apart is its antigen-agnostic approach—meaning Decoy20 doesn’t need to be tailored to specific tumor markers. Instead, it delivers a “multi-targeted package” of immune-activating signals, including Toll-like receptor (TLR), NOD-like receptor (NLR), and STING agonists, all safely administered intravenously. In preclinical models, this platform has shown not just anti-tumor, but also anti-viral activity, with hints of efficacy against chronic hepatitis B and HIV.
With 32 patients already enrolled in the weekly dosing cohorts and the combination arm now underway, Indaptus is poised for a year of pivotal data and, perhaps, a few more plot twists. Early signs suggest Decoy20 is generally well-tolerated, with instances of stable disease providing a glimmer of hope for patients and investors alike.
As CEO Jeffrey Meckler put it, this is a “crucial advancement” for the company and its Decoy platform—a sentiment echoed by analysts and, no doubt, the patients eagerly awaiting new options in their cancer journey.
In sum, Indaptus Therapeutics is betting that sometimes, the best way to outsmart cancer is not with brute force, but with a little bacterial ingenuity and a lot of immune system flair. Stay tuned: the next act could be even more dramatic.
Today, The Maxim Group's biotech analyst Jason McCarthy, Ph.D. issued an update research report titled "First Patient Dosed with decoy + Tislelizumab (PD-1) Combination in Solid Tumors Study" and included a 12-Month Target Price of $2/share. You can reach out to him at jmccarthy@maximgrp.com in order to secure a copy of the research report and learn about his valuation process.
Citations
